Modified polypeptide having glucanase activity

MYPI2025001183A0Undetermined Publication Date: 2024-02-24CJ CHEILJEDANG CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025001183
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-08-24
Filing Date
2023-08-24
Publication Date
2024-02-24

AI Technical Summary

Technical Problem

Monogastric animals have difficulty digesting and absorbing glucans due to the absence of glucanase (EC 3.2.1.73), making it challenging to efficiently utilize plant-based feed, and existing enzymes lack heat resistance for high-temperature processes.

Method used

Development of variant polypeptides with glucanase activity, specifically modifying amino acids at positions 53, 199, and 200, to enhance heat resistance and stability, allowing for effective glucan decomposition in feed and various industrial applications.

Benefits of technology

The variant polypeptides demonstrate improved heat resistance and stability, enabling efficient glucan decomposition and nutritional intake in livestock, as well as applications in feed, baking, pulp bleaching, and other industrial processes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025001183_DRAWING_001
    Figure PI2025001183_DRAWING_001
Patent Text Reader

Abstract

The present application relates to a glucanase variant.
Need to check novelty before this filing date? Find Prior Art

Description

A mutant polypeptide having glucanase activity

[0001] The present application relates to a mutant polypeptide having glucanase activity.

[0002]

[0003] 1,3-1,4-β-Glucan is a polysaccharide that constitutes the cell walls of various plants, and is particularly abundant in the cell walls of commercially valuable cereals such as barley, rye, sorghum, rice, and wheat. However, glucan acts as an antinutritional factor, hindering the digestion and absorption of plant-based feeds in animals. Monogastric animals, in particular, lack glucanase (EC 3.2.1.73), which can degrade these antinutritional factors, making it difficult for them to break down and utilize glucan.

[0004] Therefore, by adding glucanase to feed, efficient nutritional intake of livestock is possible, and for this purpose, development of glucanase suitable for feed is necessary (Murphy P, Bello FD, O'Doherty JV, Arendt EK, Sweeney T, Coffey A (2012) Effects of cereal β-glucans and enzyme inclusion on the porcine gastrointestinal tract microbiota. Anaerobe 18(6):557-565).

[0005]

[0006] Meanwhile, for feed enzymes, heat resistance to withstand high-temperature processes is essential.

[0007]

[0008] The purpose of the present application is to provide a mutant polypeptide having glucanase activity, wherein at least one amino acid corresponding to positions 53, 199 and 200 from the N-terminus of SEQ ID NO: 1 is substituted with another amino acid.

[0009] Another object of the present application is to provide a polynucleotide encoding the polypeptide of the present application.

[0010] Another object of the present application is to provide a microorganism comprising at least one of the polypeptide of the present application; a polynucleotide encoding the polypeptide; and a vector comprising the polynucleotide.

[0011] Another object of the present application is to provide a composition for decomposing glucan, comprising at least one of the polypeptide of the present application and the microorganism of the present application.

[0012] Another object of the present application is to provide a method for decomposing glucan, comprising a step of reacting at least one of the polypeptide of the present application and the microorganism of the present application with glucan.

[0013] Another object of the present application is to provide a feed additive composition comprising at least one of the polypeptide of the present application and the microorganism of the present application.

[0014] Another object of the present application is to provide a method for producing a feed product, comprising the step of mixing a feed ingredient with a feed additive composition comprising at least one of the polypeptide of the present application and the microorganism of the present application.

[0015] Another object of the present application is to provide a composition for food, a composition for food production, a detergent composition, a textile composition, and a paper-making composition, comprising at least one of the polypeptide of the present application and the microorganism of the present application.

[0016] Another object of the present application is to provide a method for producing a mutant polypeptide having glucanase activity, comprising a step of culturing the microorganism of the present application.

[0017]

[0018] The mutant polypeptide having glucanase activity of the present application has improved heat resistance and can be usefully applied to various industrial fields.

[0019]

[0020] Figure 1 shows the results of evaluating the heat resistance of enzymes C, M1, M2, and M3.

[0021]

[0022] This is explained in detail as follows. Meanwhile, each description and embodiment disclosed in this application can also be applied to each other description and embodiment. In other words, all combinations of the various elements disclosed in this application fall within the scope of this application. Furthermore, the scope of this application is not limited by the specific descriptions described below.

[0023] Furthermore, those skilled in the art will recognize or be able to ascertain, using only routine experimentation, numerous equivalents to the specific embodiments of the present application described herein. Furthermore, such equivalents are intended to be encompassed by this application.

[0024] Additionally, numerous papers and patents are referenced and cited throughout this specification. The disclosures of these cited papers and patents are incorporated herein by reference in their entirety to provide a clearer understanding of the state of the art and the scope of the present invention.

[0025]

[0026] One embodiment of the present application is a mutant polypeptide having glucanase activity, wherein at least one of the amino acids corresponding to positions 53, 199 and 200 from the N-terminus of SEQ ID NO: 1 is substituted with another amino acid.

[0027] In the present application, “variant polypeptide having glucanase activity” means a variant comprising a substitution of any one or more of the amino acids corresponding to positions 53, 199 and 200 from the N-terminus of SEQ ID NO: 1 with another amino acid in any polypeptide or glucanase having glucanase activity.

[0028]

[0029] In the present application, “glucanase” refers to an enzyme having an activity capable of cleaving a glucosidic bond connecting two glucosyl residues in glucan. Non-limiting examples of glucanase activity include endo-cellulase activity for beta-1,4 bonds between D-glucoses, or licheninase activity that cleaves (1,4)-beta-D-glucosidic bonds of beta-D-glucans containing 1,3- and 1,4-linkages. In one embodiment, the glucanase of the present application may have an activity corresponding to a glucanase classified under EC 3.2.1.73.

[0030] In one embodiment, the reference glucanase to be mutated in the present application may be a protein comprising an amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% homology or identity thereto. In addition, it is obvious that a protein having an amino acid sequence in which some sequences are deleted, modified, substituted, or added is also included within the scope of the reference protein to be mutated in the present application, as long as it has such homology or identity and exhibits an effect corresponding to the protein.

[0031] In the present application, a protein including the amino acid sequence of SEQ ID NO. 1 is defined as an example of a reference glucanase, but this does not exclude meaningless sequence additions before and after the amino acid sequence, mutations that may occur naturally, or silent mutations thereof. It does not exclude meaningless sequence additions before and after the amino acid sequence of SEQ ID NO. 1, mutations that may occur naturally, or silent mutations thereof. It is obvious to those skilled in the art that if a protein having the same or corresponding activity as the protein consisting of the amino acid sequence of SEQ ID NO. 1 can be considered a reference glucanase. Examples of other reference glucanases include glucanases derived from Orpinomyces sp., Neocallimastix sp., Piromyces sp., Clostridium sp., Rhodothermus sp., or Ruminococcus sp. Another example of a glucanase is the wild-type glucanase from the genus Orpinomyces sp.

[0032]

[0033] As used herein, the term “variant” or “modified polypeptide” refers to a protein in which one or more amino acids differ from the recited sequence by conservative substitution and / or modification, but the functions or properties of the protein are maintained.

[0034] The above variants differ from the identified sequence by several amino acid substitutions, deletions, or additions. Such variants can generally be identified by modifying one or more amino acids in the amino acid sequence of the protein and evaluating the properties of the modified protein. That is, the ability of the variant may be increased, unchanged, or decreased compared to the native protein. In addition, some variants may include variant polypeptides in which one or more portions, such as the N-terminal leader sequence or the transmembrane domain, are deleted. Other variants may include variants in which portions are deleted from the N- and / or C-terminus of the mature protein. The terms “variant” or “variant polypeptide” may be used interchangeably with terms such as variant, modification, mutated protein, and variation (in English, modification, modified protein, mutant, mutein, divergent, variant, etc.), and are not limited thereto as long as the terms are used in the meaning of variation.

[0035] As used herein, the term "conservative substitution" refers to the replacement of one amino acid with another amino acid having similar structural and / or chemical properties. Typically, conservative substitutions have little or no effect on the activity of the resulting polypeptide.

[0036] The above variants may have, for example, one or more conservative substitutions, while still retaining one or more biological activities. Such amino acid substitutions may generally be based on similarities in the polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or amphipathic nature of the residues.

[0037] Examples of these classifications include positively charged (basic) amino acids such as arginine, lysine, and histidine; negatively charged (acidic) amino acids such as glutamic acid and aspartate; amino acids with nonpolar side chains (nonpolar amino acids) such as glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, and proline; and amino acids with polar or hydrophilic side chains (polar amino acids) such as serine, threonine, cysteine, tyrosine, asparagine, and glutamine. As another example, amino acids with charged side chains (electrically charged amino acids) such as arginine, lysine, histidine, glutamic acid, and aspartate, and amino acids with uncharged side chains (also called neutral amino acids) such as glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. As another example, phenylalanine, tryptophan, and tyrosine can be classified as aromatic amino acids. As another example, valine, leucine, and isoleucine can be classified as branched amino acids. As another example, the 20 amino acids can be classified according to size, starting with a group of amino acids with relatively small volume: glycine, alanine, and serine; They can be classified into five groups: cysteine, proline, threonine, aspartate, asparagine; valine, histidine, glutamic acid, glutamine; isoleucine, leucine, methionine, lysine, arginine; and phenylalanine, tryptophan, tyrosine. However, they are not necessarily limited to this.

[0038] Additionally, variants may include deletions or additions of amino acids that have minimal impact on the properties and secondary structure of the polypeptide. For example, the polypeptide may be conjugated to a signal (or leader) sequence at the N-terminus of a protein that is involved in co-translational or post-translational protein transfer. Furthermore, the polypeptide may be conjugated to other sequences or linkers to facilitate identification, purification, or synthesis of the polypeptide.

[0039]

[0040] In one embodiment, the variant polypeptide of the present application may be a variant polypeptide having glucanase activity, wherein any one or more of the amino acids corresponding to positions 53, 199, and 200 from the N-terminus of SEQ ID NO: 1 among the above-mentioned glucanases is substituted with another amino acid.

[0041] In this application, "substitution with another amino acid" is not limited to an amino acid different from the amino acid prior to substitution. Furthermore, when this application expresses that "a specific amino acid has been substituted," it is self-evident that the amino acid has been substituted with an amino acid different from the amino acid prior to substitution, even if it is not specifically stated that it has been substituted with another amino acid.

[0042] In any one of the embodiments described above, the variant polypeptide of the present application may comprise a substitution of the amino acid corresponding to position 53 with cysteine ​​(C).

[0043] In any one of the embodiments described above, the variant polypeptide of the present application may comprise a substitution of the amino acid corresponding to position 199 with cysteine ​​(C).

[0044] In any one of the embodiments described above, the variant polypeptide of the present application may comprise a substitution of the amino acid corresponding to position 200 with proline (P).

[0045] In any one of the embodiments described above, the variant polypeptide of the present application may comprise any one or more of the following substitutions: i) substitution of the amino acid corresponding to position 53 with cysteine ​​(C); ii) substitution of the amino acid corresponding to position 199 with cysteine ​​(C); and substitution of the amino acid corresponding to position 200 with proline (P).

[0046] In any one of the embodiments described above, the variant polypeptide of the present application may comprise a substitution selected from the following: (i) a substitution of the amino acid corresponding to position 200 with proline (P); (ii) a substitution of the amino acid corresponding to position 53 with cysteine ​​(C) and a substitution of the amino acid corresponding to position 199 with cysteine ​​(C); or (iii) a substitution of the amino acid corresponding to position 200 with proline (P), a substitution of the amino acid corresponding to position 53 with cysteine ​​(C), and a substitution of the amino acid corresponding to position 199 with cysteine ​​(C).

[0047] In any one of the embodiments described above, the variant polypeptide of the present application may comprise a substitution of the amino acid corresponding to position 53 with cysteine ​​(C), and a substitution of the amino acid corresponding to position 199 with cysteine ​​(C), wherein the pair of substituted amino acids forms a disulfide bond (i.e., between the cysteine ​​residues).

[0048]

[0049] The "N-position" in the present application may include the N-position and an amino acid position corresponding to the N-position. For example, it may include an amino acid position corresponding to any amino acid residue in a mature polypeptide disclosed in a specific amino acid sequence. For example, the specific amino acid sequence may be the amino acid sequence of SEQ ID NO: 1.

[0050] As used herein, the term "corresponding to" refers to an amino acid residue at a position listed in a polypeptide, or an amino acid residue that is similar, identical, or homologous to the residue listed in the polypeptide. Identifying an amino acid at a corresponding position may be determining a specific amino acid in a sequence that references a specific sequence. As used herein, "corresponding region" generally refers to a similar or corresponding position in a related or reference protein.

[0051] In the present application, specific numbering may be used for amino acid residue positions within the protein used in the present application. For example, by aligning the polypeptide sequences of the target protein to be compared with the protein of the present application, it is possible to renumber positions corresponding to amino acid residue positions in the protein of the present application.

[0052] For example, any amino acid sequence can be aligned with SEQ ID NO: 1, and based on this, each amino acid residue of the amino acid sequence can be numbered by referring to the numerical position of the amino acid residue corresponding to the amino acid residue in SEQ ID NO: 1. For example, a sequence alignment algorithm such as that described in the present application can identify the position of an amino acid, or the position at which a modification such as a substitution, insertion, or deletion occurs, by comparing it with a query sequence (also referred to as a “reference sequence”).

[0053] For such alignment, for example, the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453), the Needleman program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000), Trends Genet. 16: 276-277) can be used, but is not limited thereto, and any sequence alignment program known in the art, pairwise sequence comparison algorithm, etc. can be appropriately used.

[0054]

[0055] In one embodiment, the variant polypeptide of the present application may comprise an amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% homology or identity thereto, wherein any one or more of the amino acids corresponding to positions 53, 199, and 200 from the N-terminus of SEQ ID NO: 1 are replaced with another amino acid.

[0056] In any one of the embodiments described above, the variant polypeptide of the present application may have one or more amino acids corresponding to positions 53, 199 and 200 from the N-terminus of SEQ ID NO: 1 replaced with another amino acid, and may have an amino acid sequence of SEQ ID NO: 1 or at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence homology or identity thereto.

[0057] In any one of the embodiments described above, the variant polypeptide of the present application may comprise an amino acid sequence of any one of SEQ ID NOs: 2 to 4.

[0058] In any one of the embodiments described above, the variant polypeptide of the present application may consist essentially of an amino acid sequence of any one of SEQ ID NOs: 2 to 4, and more specifically, may consist essentially of an amino acid sequence of any one of SEQ ID NOs: 2 to 4, but is not limited thereto.

[0059] In any one of the embodiments described above, the variant may comprise an amino acid sequence of any one of SEQ ID NOs: 2 to 4, or a sequence in which amino acids corresponding to positions 53, 199 and 200 in the amino acid sequence are fixed (i.e., in the amino acid sequence of the variant, amino acids corresponding to positions 53, 199 and 200 of the amino acid sequence of any one of SEQ ID NOs: 2 to 4 are identical to amino acids at positions 53, 199 and 200 of the amino acid sequence of any one of SEQ ID NOs: 2 to 4), and has at least 80% homology or identity therewith.

[0060] In addition, it is obvious that a protein having an amino acid sequence in which some sequences are deleted, modified, substituted or added other than one or more positions selected from positions 53, 199 and 200, as long as it has such homology or identity and exhibits an effect corresponding to the above variant, is also included in the scope of the present application.

[0061]

[0062] As used herein, the terms “homology” or “identity” refer to the degree of similarity between two given amino acid sequences or base sequences, which may be expressed as a percentage. The terms homology and identity are often used interchangeably.

[0063] Sequence homology or identity of conserved polynucleotides or polypeptides is determined by standard alignment algorithms, and may be combined with default gap penalties established by the program being used. In practice, homologous or identical sequences can generally hybridize with all or part of the sequence under moderate or high stringency conditions. It should be appreciated that hybridization also includes hybridization with polynucleotides containing common codons or codons that take codon degeneracy into account.

[0064] Whether any two polynucleotide or polypeptide sequences are homologous, similar or identical can be determined using a known computer algorithm such as the “FASTA” program using default parameters, for example as in Pearson et al (1988) [Proc. Natl. Acad. Sci. USA 85]: 2444. Alternatively, the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) as implemented in the Needleman program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277) (version 5.0.0 or later) can be determined using the GCG program package (Devereux, J., et al, Nucleic Acids Research 12: 387(1984)), BLASTP, BLASTN, FASTA (Atschul, [S.] [F.,] [ET AL, J MOLEC BIOL 215]: 403 (1990); Guide to Huge Computers, Martin J. Bishop, [ED.,] Academic Press, San Diego, 1994, and [CARILLO et al.](1988) SIAM J Applied Math 48: 1073). For example, homology, similarity, or identity can be determined using BLAST or ClustalW from the National Center for Biotechnology Information database.

[0065] Homology, similarity, or identity of polynucleotides or polypeptides can be determined by comparing sequence information, for example, using a GAP computer program such as that of Needleman et al. (1970), J Mol Biol. 48:443, as disclosed, for example, in Smith and Waterman, Adv. Appl. Math (1981) 2:482. In brief, the GAP program can be defined as the total number of symbols in the shorter of the two sequences divided by the number of similarly arranged symbols (i.e., nucleotides or amino acids). Default parameters for the GAP program include (1) a unitary comparison matrix (containing values ​​of 1 for identity and 0 for non-identity) and (2) a quantile comparison matrix as disclosed by Gribskov et al. (1986) Nucl. Acids Res. 48:443, as disclosed by Schwartz and Dayhoff, eds., Atlas Of Protein Sequence And Structure, National Biomedical Research Foundation, pp. 353-358 (1979). 14: 6745 weighted comparison matrix (or EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix); (2) a penalty of 3.0 for each gap and an additional penalty of 0.10 for each symbol in each gap (or a gap opening penalty of 10 and a gap extension penalty of 0.5); and (3) no penalty for terminal gaps. Accordingly, the term “homology” or “identity” as used in this application refers to the relevance between sequences.

[0066]

[0067] In the present application, “enzymatic activity” or “glucanase activity” refers to at least one catalytic activity. Specifically, it may be, but is not limited to, the conversion efficiency of an enzyme, which is mainly expressed as kcat / Km.

[0068] kcat is the catalytic constant for the conversion of a single enzyme into a product per unit time when the enzyme is completely saturated with substrate, and is also called the turnover number. Km is the substrate concentration when the reaction rate is half of the maximum value (Vmax).

[0069] As an example of how to express enzyme activity, specific activity (umol of converted substrate x mg) -1 x min -1 ) or volumetric activity (umol of converted substrate x mL -1 x min -1). However, defining enzyme activity is not limited to the above-mentioned content, and can be defined and evaluated based on content known in the art.

[0070] In this application, enzyme stability refers to the preservation of enzyme activity during storage or reaction time. To measure changes in this stability, the initial enzyme activity is measured at time zero (100%) and after a specified time (x%) under specified conditions, and compared. This allows for the expression of the level of enzyme activity loss or enzyme stability.

[0071] Factors that affect enzyme activity include, for example, pH, heat, and the presence of other substances (e.g., oxidizing agents, chelating agents).

[0072]

[0073] As used herein, the term "thermal stability" refers to the ability of a protein to function within a specific temperature range. In one embodiment, the variant polypeptide provided in the present application may be active in a temperature range of about 20°C to about 120°C, and specifically, may be active in a temperature range of about 60°C to about 100°C.

[0074] As used herein, the term "thermal tolerance" refers to the ability of a protein to function after exposure to a specific temperature, such as high or extremely low temperatures. For example, a protein exhibiting heat tolerance may not function at the temperature to which it is exposed, but may regain function upon returning to its optimal temperature environment. In one embodiment, the variant polypeptides provided in the present application can maintain their ability to function after exposure to high temperatures ranging from about 60°C to about 100°C.

[0075] Increased stability or heat resistance includes maintaining high enzymatic activity compared to other enzymes, e.g., wild-type enzymes, parent enzymes, and / or other mutant polypeptides; or increasing the range of pH, temperature, and / or time over which the protein remains functional.

[0076] In one embodiment, the variant polypeptide provided in the present application may have improved heat resistance and / or heat stability compared to the polypeptide of SEQ ID NO: 1.

[0077] In one embodiment, the mutant polypeptide provided in the present application may have improved heat resistance and / or heat stability compared to the wild-type polypeptide.

[0078] In one embodiment, the variant polypeptide provided in the present application may have improved heat resistance compared to the polypeptide of SEQ ID NO: 1.

[0079] In any one of the embodiments described above, the properties of the variant polypeptide provided in the present application may be activity or improved activity suitable for application in various industrial fields including feed, baking, pulp bleaching, etc.

[0080]

[0081] Another aspect of the present application is a polynucleotide encoding a variant polypeptide of the present application.

[0082] In this application, the term “polynucleotide” means a DNA or RNA strand of a certain length or longer, which is a polymer of nucleotides in which nucleotide units (monomers) are linked in a long chain shape by covalent bonds.

[0083] The polynucleotide encoding the variant polypeptide of the present application may include, without limitation, any polynucleotide encoding the variant polypeptide of the present application and a polypeptide having a corresponding activity.

[0084] The polynucleotide encoding the variant polypeptide of the present application may have various modifications made to the coding region within a range that does not change the amino acid sequence of the polypeptide due to the degeneracy of the codon or taking into account the codon preferred in the organism that is to express the polypeptide.

[0085] In one embodiment, a polynucleotide encoding a variant polypeptide of the present application may have or comprise a base sequence that is at least 50%, 60%, 70%, 75%, 80%, 85%, or 90% homologous or identical, but less than 100%, to the polynucleotide sequence of SEQ ID NO: 5.

[0086] In any one of the above-described embodiments, the polynucleotide encoding the glucanase variant of the present application may have or include a base sequence having at least 50%, 60%, 70%, 75%, 80%, 85%, or 90% homology or identity with the polynucleotide sequence of SEQ ID NO: 5, but less than 100%, wherein in the sequence having the homology or identity, the codon encoding the amino acid corresponding to position 53 from the N-terminus of SEQ ID NO: 1 is one of the codons encoding an amino acid other than arginine (R); the codon encoding the amino acid corresponding to position 199 is one of the codons encoding an amino acid other than threonine (T); the codon encoding the amino acid corresponding to position 200 is one of the codons encoding an amino acid other than asparagine (N); or a combination thereof.

[0087] In any one of the above-described embodiments, the polynucleotide encoding the glucanase variant of the present application may have or include a base sequence having at least 50%, 60%, 70%, 75%, 80%, 85% or 90% homology or identity with the polynucleotide sequence of SEQ ID NO: 5, but less than 100%, and in the sequence having the homology or identity, the codon encoding the amino acid corresponding to position 53 from the N-terminus of SEQ ID NO: 1 and / or the amino acid corresponding to position 199 may be one of the codons encoding cysteine ​​(C), and / or the codon encoding the amino acid corresponding to position 200 may be one of the codons encoding proline (P).

[0088]

[0089] Additionally, the polynucleotide of the present application may include, without limitation, a probe that can be prepared from a known genetic sequence, for example, a sequence that can hybridize under stringent conditions with a complementary sequence to all or part of the polynucleotide sequence of the present application.

[0090] The above “stringent conditions” refer to conditions that enable specific hybridization between polynucleotides. These conditions are specifically described in the literature (see J. Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press, Cold Spring Harbor, New York, 1989; FM Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., New York, 9.50-9.51, 11.7-11.8). For example, conditions in which polynucleotides having high homology or identity hybridize with each other, polynucleotides having 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more homology or identity hybridize with each other, and polynucleotides having lower homology or identity do not hybridize with each other, or conditions in which washing is performed once, specifically twice or three times, at a salt concentration and temperature equivalent to the washing conditions of a typical southern hybridization, 60°C 1×SSC, 0.1% SDS, specifically 60°C 0.1×SSC, 0.1% SDS, and more specifically 68°C 0.1×SSC, 0.1% SDS, are performed.

[0091] Hybridization requires that two nucleic acids have complementary sequences, although mismatches between bases are possible depending on the stringency of hybridization. The term "complementary" is used to describe the relationship between nucleotide bases that can hybridize with each other. For example, in DNA, adenine is complementary to thymine, and cytosine is complementary to guanine. Therefore, the polynucleotides of the present application may also include isolated nucleic acid fragments that are complementary in their entirety, as well as substantially similar nucleic acid sequences.

[0092] Specifically, a polynucleotide having homology or identity with the polynucleotide of the present application can be detected using hybridization conditions including a hybridization step at a Tm value of 55°C and using the conditions described above. In addition, the Tm value may be, but is not limited to, 60°C, 63°C, or 65°C, and can be appropriately adjusted by a person skilled in the art depending on the purpose.

[0093] The appropriate stringency for hybridizing the polynucleotides depends on the length and degree of complementarity of the polynucleotides, variables which are well known in the art (e.g., J. Sambrook et al., supra).

[0094]

[0095] Another aspect of the present application provides a vector comprising a polynucleotide encoding a variant polypeptide of the present application. The variant polypeptide and polynucleotide are as described in the other aspects above.

[0096] The term “vector” as used herein refers to a DNA construct containing a base sequence of a polynucleotide encoding a target polypeptide operably linked to a suitable expression control region (or expression control sequence) so as to enable expression of the target polypeptide in a suitable host. The expression control region may include a promoter capable of initiating transcription, an optional operator sequence for regulating such transcription, a sequence encoding a suitable mRNA ribosome binding site, and sequences regulating the termination of transcription and translation. After being transformed into a suitable host cell, the vector may replicate or function independently of the host genome, or may be integrated into the genome itself.

[0097] For example, a polynucleotide encoding a target protein within a chromosome can be replaced with a mutated polynucleotide through a vector for intracellular chromosomal insertion. The insertion of the polynucleotide into the chromosome can be accomplished by any method known in the art, such as, but not limited to, homologous recombination. A selection marker for confirming the chromosomal insertion can be additionally included. The selection marker is used to select cells transformed with the vector, i.e., to confirm the insertion of the target nucleic acid molecule. Markers that confer a selectable phenotype, such as drug resistance, nutrient requirement, cytotoxic agent resistance, or expression of a surface protein, can be used. In an environment treated with a selective agent, only cells expressing the selection marker survive or exhibit other phenotypic traits, thereby allowing the selection of transformed cells.

[0098] The vector used in this application is not particularly limited, and any vector known in the art can be used.

[0099] Examples of vectors commonly used in prokaryotes include pWE15, M13, MBL3, MBL4, IXII, ASHII, APII, t10, t11, Charon4A, and Charon21A, which can be used as phage vectors or cosmid vectors, and pBR series, pUC series, pBluescriptII series, pGEM series, pTZ series, pCL series, and pET series, which can be used as plasmid vectors. Specifically, pDZ, pACYC177, pACYC184, pCL, pECCG117, pUC19, pBR322, pMW118, pCC1BAC, and pDCM2 vectors, etc. can be used.

[0100] As an example of a vector used in a eukaryotic cell, the yeast expression vector can be both an integrative yeast plasmid (YIp) and an extrachromosomal plasmid vector. The extrachromosomal plasmid vector can include an episomal yeast plasmid (YEp), a replicative yeast plasmid (YRp), and a yeast centromer plasmid (YCp). In addition, artificial yeast chromosomes (YACs) can also be used as the vector of the present application. As specific examples, available vectors include pESCHIS, pESC-LEU, pESC-TRP, pESC-URA, Gateway pYES-DEST52, pAO815, pGAPZ A, pGAPZ B, pGAPZ C, pGAPα A, pGAPα B, pGAPα C, pPIC3.5K, pPIC6 A, pPIC6 B, pPIC6 C, pPIC6α A, pPIC6α B, pPIC6α C, pPIC9K, pYC2 / CT, pYD1 Yeast Display Vector, pYES2, pYES2 / CT, pYES2 / NT A, pYES2 / NT B, pYES2 / NT C, pYES2 / CT, pYES2.1, pYES-DEST52, pTEF1 / Zeo, pFLD1, PichiaPinkTM, p427-TEF, p417-CYC, pGAL-MF, p427-TEF, p417-CYC, PTEF-MF, pBY011, pSGP47, pSGP46, pSGP36, pSGP40, ZM552, pAG303GAL-ccdB, pAG414GAL-ccdB, pAS404, pBridge, pGAD-GH, pGAD T7, pGBK T7, pHIS-2, pOBD2, pRS408, pRS410, pRS418, pRS420, pRS428, yeast micron A form, pRS403, pRS404, pRS405, pRS406, pYJ403, Including but not limited to pYJ404, pYJ405 and pYJ406.

[0101] The term "transformation" in this application refers to introducing a vector containing a polynucleotide encoding a target protein into a host cell or microorganism, thereby enabling expression of the protein encoded by the polynucleotide within the host cell. The transformed polynucleotide may be located within the chromosome of the host cell or located outside the chromosome, as long as it can be expressed within the host cell. Furthermore, the polynucleotide includes DNA and RNA encoding the target protein. The polynucleotide may be introduced in any form as long as it can be introduced into the host cell and expressed. For example, the polynucleotide may be introduced into the host cell in the form of an expression cassette, which is a genetic construct containing all elements necessary for autonomous expression. The expression cassette may typically include a promoter, a transcription termination signal, a ribosome binding site, and a translation termination signal, all of which are operably linked to the polynucleotide. The expression cassette may be in the form of a self-replicating expression vector. Additionally, the polynucleotide may be introduced into a host cell in its own form and operably linked to a sequence necessary for expression in the host cell, but is not limited thereto.

[0102] Additionally, the term “operably linked” as used above means that the gene sequence is functionally linked to a promoter sequence that initiates and mediates transcription of a polynucleotide encoding the target polypeptide of the present application.

[0103] The method for transforming the vector of the present application includes any method for introducing nucleic acids into cells, and can be performed by selecting an appropriate standard technique known in the art depending on the host cell. Examples include, but are not limited to, electroporation, calcium phosphate (CaPO4) precipitation, calcium chloride (CaCl2) precipitation, microinjection, polyethylene glycol (PEG) method, DEAE-dextran method, cationic liposome method, and lithium acetate-DMSO method.

[0104]

[0105] Another aspect of the present application is a microorganism comprising at least one of a variant polypeptide of the present application; a polynucleotide encoding the variant polypeptide; and a vector comprising the variant polypeptide.

[0106] The above microorganism may comprise the above-described variant polypeptide, a polynucleotide encoding the same, a nucleic acid construct comprising the polynucleotide, and / or a vector. The nucleic acid construct or vector may be integrated into a chromosome or maintained as an extrachromosomal vector that replicates autonomously.

[0107] The microorganism of the present application may be any cell capable of expressing the variant polypeptide of the present application without limitation. For example, any cell useful for recombinant production of the variant polypeptide of the present application is included, and for example, the microorganism may be a prokaryotic cell or a eukaryotic cell. In other examples, examples of the microorganism include fungi and bacteria.

[0108] In one embodiment, the microorganism of the present application may be a microorganism of the genus Escherichia, such as Escherichia coli, Escherichia albertii, Escherichia fergusonii, Escherichia hermannii, Escherichia vulneris, or Escherichia blattae. In any one of the aforementioned embodiments, the microorganism may be, but is not limited to, Escherichia coli.

[0109]

[0110] Another aspect of the present application is a composition for decomposing glucan, comprising at least one of a variant polypeptide of the present application; and a microorganism comprising at least one of the variant polypeptide, a polynucleotide encoding the variant polypeptide, and a vector comprising the polynucleotide. Another aspect of the present application is a use of a composition for decomposing glucan, comprising at least one of a variant polypeptide of the present application; and a microorganism comprising at least one of the variant polypeptide, a polynucleotide encoding the variant polypeptide, and a vector comprising the polynucleotide.

[0111] Another aspect of the present application is a method for decomposing glucan, comprising the step of reacting at least one of a microorganism comprising a variant polypeptide of the present application; and at least one of the variant polypeptide, a polynucleotide encoding the variant polypeptide, and a vector comprising the polynucleotide; with glucan.

[0112] A microorganism comprising at least one of the variant polypeptides of the present application and / or the variant polypeptides, the polynucleotides encoding the variant polypeptides, and the vectors comprising the polynucleotides can be used to decompose a material containing glucan.

[0113] In one embodiment, the composition for decomposing glucan provided in the present application may further include a naturally occurring substance or a non-naturally occurring substance in addition to the mutant polypeptide of the present application.

[0114] In one embodiment, the composition for decomposing glucan provided in the present application may further include any component suitable for application in various industrial fields such as animal feed, baking, biomass saccharification, and pulp bleaching.

[0115] Examples of substances that may be added include, but are not limited to, stabilizers, surfactants, builders, chelating agents, dispersants, enzymes, enzyme stabilizers, catalysts, activators, carriers, admixtures, lubricants, disintegrants, excipients, solubilizers, suspending agents, colorants, flavorings, buffers, preservatives, analgesics, solubilizers, isotonic agents, diluents, lubricants, and the like.

[0116]

[0117] Another aspect of the present application is a feed additive composition comprising at least one of a variant polypeptide of the present application; and a microorganism comprising at least one of the variant polypeptide, a polynucleotide encoding the variant polypeptide, and a vector comprising the polynucleotide.

[0118] Another aspect of the present application is a method for producing a feed product, comprising the step of mixing a feed additive composition with a feed ingredient, at least one of a variant polypeptide of the present application; and a microorganism comprising at least one of the variant polypeptide, a polynucleotide encoding the variant polypeptide, and a vector comprising the polynucleotide.

[0119] The variant polypeptide of the present application or the microorganism of the present application may be used in any of the following applications:

[0120] a) additives in animal feed ingredients; and / or

[0121] b) animal feed supplements; and / or

[0122] c) Decomposition of grain-based materials (e.g., this may be whole grains or parts of grains).

[0123] The feed product of the present application may mean any natural or artificial diet, meal, etc. or ingredients of the meal for eating, ingesting, and digesting by animals or suitable therefor, and may be manufactured in various forms known in the art.

[0124] The mutant polypeptides of the present invention having glucanase activity can be used in various industrial fields such as food, paper, pulp, detergent, industrial waste treatment, biomaterials, and bioenergy. For industrial applications of glucanase, see McCarthy TC, Lalor E, Hanniffy O, Savage AV, Tuohy MG, Comparison of wide-type and UV-mutant βglucanase-producing strains of Talaromyces emersonii with potential in brewing applications, J Ind Microbiol Biotechnol, 2005; Chaari F, Belghith-Fendri L, Blibech M, Driss D, Ellouzia SZ, Sameh M, Ellouz-Chaabouni S, Biochemical characterization of a lichenase from Penicillium occitanis Pol6 and its potential application in the brewing industry, Process Biochem, 2014; Reference may be made to the literature such as Maktouf S, Moulis C, Kamoun A, Chaari F, Chaabouni SE, Remaud-Simeon M, A laundry detergent compatible lichenase: statistical optimization for production under solid state fermentation on crude millet, Ind Crops Prod, 2013.

[0125] One embodiment of the present application is a food composition comprising a variant polypeptide having glucanase activity of the present application or a microorganism of the present application; or a composition for producing a food. For example, glucanase can be used in brewing (beer, wine, etc.) and producing fruit juice. Glucanase can be added during the saccharification process to lower wort viscosity, improve filtration performance, increase malt dissolution rate, prevent beer turbidity, and stabilize beer quality.

[0126] Another aspect of the present application is a detergent composition comprising a variant polypeptide having glucanase activity of the present application or a microorganism of the present application. A detergent composition is a composition used to remove unwanted compounds from items to be washed, such as fabrics, dishes, or hard surfaces. Examples of detergent compositions include fabric detergents, fabric cleaners, hard surface cleaners such as glass, wood, plastic, ceramic, and metal countertops and windows, carpet cleaners, oven cleaners, fabric fresheners, fabric softeners, and dishwashing detergents.

[0127] Another aspect of the present application is a textile composition comprising a variant polypeptide having glucanase activity of the present application or a microorganism of the present application. The glucanase of the present application can be used in the processing of fibers for the manufacture of garments. Such processing includes processing such as bleaching, removal of dye after dyeing, and biopolishing of cotton or cotton blend fabrics.

[0128] Another aspect of the present application is a composition for paper processing, comprising a variant polypeptide having glucanase activity of the present application or a microorganism of the present application. The variant polypeptide having glucanase activity of the present application can be used to improve wastewater, remove ink, or decolorize in the pulp industry.

[0129] In any of the aforementioned embodiments, the composition provided by the present application may further comprise any component suitable for application in various industrial fields. In any of the aforementioned embodiments, the composition provided by the present application may further comprise any other enzyme suitable for use in the intended application.

[0130] In any one of the embodiments described above, the composition provided in the present application may comprise a variant polypeptide having glucanase activity of the present application or a microorganism of the present application in an amount suitable for use in the intended use.

[0131] In any of the embodiments described above, the composition provided in the present application may be provided in a form suitable for use in its intended purpose. By way of non-limiting example, the composition may be in the form of a bar, tablet, powder, granule, paste, or liquid.

[0132]

[0133] Another aspect of the present application is a method for producing a variant polypeptide having glucanase activity, comprising the step of culturing a microorganism comprising at least one of a variant polypeptide of the present application, a polynucleotide encoding the variant polypeptide, and a vector comprising the polynucleotide.

[0134] The above culturing may include a step of culturing the microorganism in a culture medium.

[0135] In this application, the term "cultivation" refers to growing the host cells under appropriately controlled environmental conditions. The culturing process of this application can be performed using any suitable medium and culture conditions known in the art. This culturing process can be easily adjusted and used by those skilled in the art depending on the selected strain. Specifically, the culturing process may be batch, continuous, or fed-batch, but is not limited thereto.

[0136] In this application, the term “medium” refers to a material containing nutrients as a main component necessary for culturing the host cells, and supplies nutrients and growth factors, including water essential for survival and development. Specifically, the medium and other culture conditions used for culturing the host cells of the present application may be any medium used for culturing conventional host cells without particular limitation, but the host cells of the present application may be cultured under aerobic conditions while controlling temperature, pH, etc. in a conventional medium containing an appropriate carbon source, nitrogen source, phosphorus source, inorganic compound, amino acid, and / or vitamin.

[0137] In the present application, the carbon source may include carbohydrates such as glucose, saccharose, lactose, fructose, sucrose, maltose, etc.; sugar alcohols such as mannitol, sorbitol, etc.; organic acids such as pyruvic acid, lactic acid, citric acid, etc.; amino acids such as glutamic acid, methionine, lysine, etc. In addition, natural organic nutrients such as starch hydrolysate, molasses, blackstrap molasses, rice winter, cassava, sugarcane bagasse, and corn steep liquor may be used, and specifically, carbohydrates such as glucose and sterilized pretreated molasses (i.e., molasses converted into reducing sugar) may be used, and other appropriate amounts of carbon sources may be used in various ways without limitation. These carbon sources may be used alone or in combination of two or more, but are not limited thereto.

[0138] The nitrogen source may include inorganic nitrogen sources such as ammonia, ammonium sulfate, ammonium chloride, ammonium acetate, ammonium phosphate, ammonium carbonate, ammonium nitrate, etc.; organic nitrogen sources such as amino acids such as glutamic acid, methionine, glutamine, etc.; peptone, NZ-amine, meat extract, yeast extract, malt extract, corn steep liquor, casein hydrolysate, fish or its decomposition product, defatted soybean cake or its decomposition product, etc. These nitrogen sources may be used alone or in combination of two or more, but are not limited thereto.

[0139] The above-mentioned components may include potassium phosphate monobasic, potassium phosphate dibasic, or their corresponding sodium-containing salts. Inorganic compounds may include sodium chloride, calcium chloride, iron chloride, magnesium sulfate, iron sulfate, manganese sulfate, calcium carbonate, etc. In addition, amino acids, vitamins, and / or suitable precursors may be included. These components or precursors may be added to the medium in batch or continuous manner, but are not limited thereto.

[0140] In addition, during the cultivation of the host cells, compounds such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid, sulfuric acid, etc. can be added to the medium in an appropriate manner to adjust the pH of the medium. In addition, during the cultivation, foaming can be suppressed by using an antifoaming agent such as fatty acid polyglycol ester. In addition, in order to maintain the aerobic state of the medium, oxygen or an oxygen-containing gas can be injected into the medium, or in order to maintain the anaerobic and microaerobic state, nitrogen, hydrogen, or carbon dioxide gas can be injected without injecting gas, but is not limited thereto.

[0141] The temperature of the medium may be, but is not limited to, 20°C to 55°C, specifically 25°C to 40°C. The incubation period may continue until the desired amount of useful substances is obtained, and specifically may be, but is not limited to, 24 hours to 196 hours.

[0142] In one embodiment, the method for producing a variant polypeptide of the present application may further include a step of recovering the variant polypeptide of the present application expressed in the culturing step.

[0143] In another embodiment, the mutant polypeptide expressed in the above-described culturing step can be recovered using methods known in the art. For example, the mutant polypeptide can be recovered from the medium by conventional procedures including, but not limited to, collection, centrifugation, filtration, extraction, spray-drying, evaporation, or precipitation.

[0144] The above recovery method may be to collect the polypeptide using a suitable method known in the art according to the culture method of the microorganism of the present application, such as a batch, continuous or fed-batch culture method. For example, various chromatographies such as centrifugation, filtration, treatment with a crystallizing protein precipitant (salting out method), extraction, ultrasonic disruption, ultrafiltration, dialysis, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, affinity chromatography, HPLC and a combination of these methods may be used, and the variant of the present application may be recovered from a medium or host cell using a suitable method known in the art.

[0145] In another embodiment, the variant polypeptide expressed by the host cell during the culture step may not be recovered. In this embodiment, the host cell itself expressing the variant polypeptide may be used as a source of the variant polypeptide.

[0146]

[0147] Another aspect of the present application is a composition comprising at least one of a variant polypeptide of the present application; and a microorganism comprising at least one of the polypeptide, a polynucleotide encoding the variant polypeptide, and a vector comprising the polynucleotide.

[0148] As described above, the composition can be used for food, feed additives, food manufacturing, detergents, textiles, or papermaking. Another aspect of the present application provides uses of the composition for food, feed additives, food manufacturing, detergents, textiles, or papermaking. This is as described in the above aspect.

[0149]

[0150] Hereinafter, this application will be described in more detail through examples and experimental examples. However, these examples and experimental examples are intended to exemplify this application and the scope of this application is not limited to these examples and experimental examples.

[0151]

[0152] Example 1. Production of a protein having glucanase activity

[0153] Example 1-1. Production of mutant recombinant plasmids

[0154] Three mutants, M1 (SEQ ID NO: 2), M2 (SEQ ID NO: 3), and M3 (SEQ ID NO: 4), were produced based on a synthetic sequence C (SEQ ID NO: 1) generated from a gene derived from the genomic DNA of Orpinomyces sp. PC-2 strain.

[0155] PCR was performed under the following conditions to amplify mutant genes for cloning. Specifically, templates, primers, and PCR premix (Taq 2X premix, Bioneer) were used for PCR production. M1 used the synthetic sequence C as a template and the M1-F and M1,R primers. M2 used the synthetic sequence C as a template and the M2-F1, M2-F2, M2-R1, and M2-R2 primers. M3 used M2 as a template and the M3-F and M3R primers.

[0156] PCR was performed using Eppendorf Mastercycler Nexus GX2, and the reaction conditions were as follows.

[0157] Initial denaturation: -95℃, 2min

[0158] Denaturation: -95℃, 20sec

[0159] Annealing: - 50℃, 10sec

[0160] Extension: - 72℃, 1 min (30 cycles from denaturation to extension)

[0161] Final Extension: - 72℃, 5min

[0162]

[0163] The amplified gene was cloned into the pET28a vector using the In-Fusion HD cloning kit (Takara, Cat. No. 639650).

[0164] PrimerSequence>M1-FAACGGCCGTACCCCGATTAGGCGCGTAT>M1-RATACGCGCTAATCGGGGTACGGCCGTT>M2-F1TTGACCATTGACTGCGATGGCAGCGGT>M2-F2TTTAACGGCCGTTGCAATAT TAGCGCG>M2-R1ACCGCTGCCATCGCAGTCAATGGTCAA>M2-R2CGCGCTAATATTGCAACGGCCGTTAAA>M3-FAACGGCCGTTGCCCGATTAGGCGCGTAT>M3-RATACGCGCTAATCGGGCAACGGCCGTT

[0165]

[0166] Mutants M1, M2, and M3 have mutations in the following sites. In M1, asparagine at position 200 of SEQ ID NO: 1 is substituted with proline. In M2, arginine at position 53 of SEQ ID NO: 1 is substituted with cysteine, and threonine at position 199 is substituted with cysteine. In M3, arginine at position 53 of SEQ ID NO: 1 is substituted with cysteine, threonine at position 199 is substituted with cysteine, and asparagine at position 200 is substituted with proline.

[0167]

[0168] Example 1-2. Production of transformants containing glucanase genes and enzyme expression

[0169] The recombinant plasmid constructed in Example 1-1 was transformed into E. coli BL21. Then, to produce glucanase mutants, the transformants were inoculated into 5 ml of LB medium and cultured at 37℃ for 18 hours. For the main culture, 5 ml of the pre-culture was inoculated into 300 ml of LB medium and cultured at 37℃. Then, when the OD600 value was between 0.4 and 0.6, 120 ul of 1 M IPTG was added and cultured for an additional 12 hours. The cells were recovered by centrifugation and redispersed in 35 ml of lysis buffer (50 mM Tris-HCl pH 8.0, 100 mM NaCl, 10 mM imidazole).

[0170]

[0171] Example 1-3. Purification of a polypeptide having glucanase activity

[0172] The cells in the dispersion were disrupted using an ultrasonic disperser, and the supernatant, a crude enzyme solution, was obtained through centrifugation. The crude enzyme solution was adsorbed by flowing it on Ni-NTA resin (Qiagen, Cat no. 30230), and then washing buffer (20 mM imidazole concentration in lysis buffer composition) and elution buffer (250 mM imidazole concentration in lysis buffer composition) were sequentially flowed to obtain a polypeptide with purified glucanase activity.

[0173]

[0174] Example 2. Evaluation of heat resistance of glucanase variants

[0175] Example 2-1. Measurement of residual activity of glucanase variants

[0176] To evaluate the heat resistance of the mutants, each purified enzyme was incubated at 75°C and 80°C for 5 minutes. Then, to measure the activity of the heat-treated enzyme, 50 μl of 1% glucan, 5 μl of 1 M buffer, and an appropriate amount of the enzyme before and after heat treatment were mixed, and the final volume was adjusted to 100 μl with triple-distilled water. After mixing the mixture well, the reaction was performed at 37°C, and the produced reducing sugar was measured using the DNS method. The DNS solution preparation method is as follows. Add 6.3 g of 3,5-dinitrosalicylic acid (samchus, D1267) to 500 ml of distilled water, dissolve by adding 21 g of sodium hydroxide (Daejung, 7571-4400) at 50℃, add 182 g of potassium sodium tartrate tetrahydrate (Daejung, 6618-4400) and 5 g of phenol (Sigma-Aldrich, P1037), add 300 ml of distilled water, add 5 g of sodium sulfite anhydrous (Daejung, 7634-4405), stir until dissolved, cool, adjust to a final volume of 1000 ml with distilled water, and filter to prepare.

[0177]

[0178] Example 3. Results of heat resistance evaluation of mutants

[0179] To evaluate the heat resistance of proteins and variants having glucanase activity, purified enzymes C, M1, M2, and M3 prepared in Examples 1-3 were left at 75°C and 80°C for 5 minutes each. Then, the residual activity of these heat-treated enzymes was confirmed at 37°C.

[0180] As a result, all three mutants (M1, M2, and M3) showed improved heat resistance compared to C. When the enzyme activity at 37°C before heat treatment was set to 100%, M1 showed 54% and M2 showed 70% at 80°C, showing heat resistance improved by more than 50% compared to 1% of C. In addition, M3 showed excellent residual activity of more than 92%.

[0181]

[0182] From the above description, those skilled in the art will understand that the present application can be implemented in other specific forms without altering its technical concept or essential characteristics. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. The scope of this application should be interpreted to include all changes or modifications derived from the meaning and scope of the following claims and their equivalents, rather than the detailed description above.

Claims

1. A mutant polypeptide having glucanase activity, wherein at least one amino acid corresponding to positions 53, 199, and 200 from the N-terminus of sequence number 1 is substituted with another amino acid.

2. A variant polypeptide having glucanase activity, wherein the variant polypeptide comprises one or more of the following substitutions: i) Substitution of the amino acid corresponding to position 53 with cysteine ​​(C); ii) substitution of the amino acid corresponding to position 199 with cysteine ​​(C); and iii) Substitution of the amino acid corresponding to position 200 with proline (P); 3. In the first paragraph, the mutant polypeptide has glucanase activity, wherein the mutant polypeptide comprises a substitution selected from the following; (i) substitution of the amino acid corresponding to position 200 with proline (P); (ii) substitution of the amino acid corresponding to position 53 with cysteine ​​(C) and substitution of the amino acid corresponding to position 199 with cysteine ​​(C); or (iii) Substitution of the amino acid corresponding to position 53 with cysteine ​​(C), substitution of the amino acid corresponding to position 199 with cysteine ​​(C), and substitution of the amino acid corresponding to position 200 with proline (P).

4. A variant polypeptide having glucanase activity, wherein the variant polypeptide comprises a substitution of an amino acid corresponding to position 53 with cysteine ​​(C) and a substitution of an amino acid corresponding to position 199 with cysteine ​​(C), and a modification such that the amino acid pair forms a disulfide bond.

5. A mutant polypeptide having glucanase activity, wherein the mutant polypeptide comprises any one amino acid sequence selected from among SEQ ID NOs: 5 to 7, in the first paragraph.

6. A polypeptide according to claim 1, wherein the mutant polypeptide has improved heat resistance compared to the polypeptide of sequence number 1.

7. A polynucleotide encoding a mutant polypeptide of any one of claims 1 to 6.

8. A microorganism comprising at least one of a variant polypeptide of any one of claims 1 to 6; a polynucleotide encoding the variant polypeptide; and a vector comprising the polynucleotide.

9. A mutant polypeptide of any one of claims 1 to 6; and A microorganism comprising at least one of a variant polypeptide of any one of claims 1 to 6, a polynucleotide encoding the variant polypeptide, and a vector comprising the polynucleotide. A composition for decomposing glucan, comprising at least one of:

10. A mutant polypeptide of any one of claims 1 to 6; and A microorganism comprising at least one of a variant polypeptide of any one of claims 1 to 6, a polynucleotide encoding the variant polypeptide, and a vector comprising the polynucleotide. A method for decomposing glucan, comprising a step of reacting at least one of the above with glucan.

11. A mutant polypeptide of any one of claims 1 to 6; and A microorganism comprising at least one of a variant polypeptide of any one of claims 1 to 6, a polynucleotide encoding the variant polypeptide, and a vector comprising the polynucleotide. A composition comprising at least one of:

12. A mutant polypeptide of any one of claims 1 to 6; and A microorganism comprising at least one of a variant polypeptide of any one of claims 1 to 6, a polynucleotide encoding the variant polypeptide, and a vector comprising the polynucleotide. A feed additive composition comprising at least one of: A method for manufacturing a feed product, comprising the step of mixing feed ingredients.

13. A composition according to claim 11, wherein the composition is for food, feed additive, food manufacturing, detergent, textile, or paper manufacturing.

14. A method for producing a polypeptide having glucanase activity, comprising the step of culturing a microorganism comprising at least one of a variant polypeptide of any one of claims 1 to 6; a polynucleotide encoding the variant polypeptide; and a vector comprising the polynucleotide.